Critically Appraised Topic: Weight Gain Following Discontinuation Of Semaglutide In Nondiabetic Patients

This is an accepted article with a DOI pre-assigned that is not yet published.Clinical Question: Should weight gain be expected following cessation of semaglutide treatment in obese, nondiabetic patients? Patient/Population: (n=1961) Nondiabetic and BMI ≥ 30 or BMI ≥ 27 & ≥ 1 weight-related comorbidities Intervention: Lifestyle interventions + Semaglutide 2.4 mg SQ once weekly for 68 weeks (including 16-weeks of dose escalation) followed by an additional year of monitoring following discontinuation of semaglutide and lifestyle interventions. Comparison: Lifestyle interventions + Placebo SQ injections for 68-weeks followed by additional year of monitoring following discontinuation of lifestyle interventions and placebo injections. Outcome: Weight gain, Cardiometabolic variables (Blood pressure, cholesterol, CRP, HgbA1C) Type of study: Randomized Control Trial